Работы, на которые ссылается эта работа

Работ: 189

Работа: Innovations in cancer immunotherapy: A comprehensive overview of recent breakthroughs and future directions

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
Evanthia Galanis, Lynn C. Hartmann, William A. Cliby +17
Статья2010Цитирований: 2
ABI
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Gregory L. Beatty, Andrew R. Haas, Marcela V. Maus +9
Статья2013Цитирований: 2
ABI
Oncolytic Viruses: Exploiting Cancer's Deal with the Devil
Larissa A. Pikor, John C. Bell, Jean‐Simon Diallo
Обзорная статья2015Цитирований: 2
ABI
Harnessing the immune system to improve cancer therapy
Nikos E. Papaioannou, Ourania V. Beniata, Panagiotis Vitsos +2
Обзорная статья2016Цитирований: 2
ABI
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment
Hila Magen, Eli Muchtar
Обзорная статья2016Цитирований: 2
ABI
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Larysa Sanchez, Yucai Wang, David S. Siegel +1
Обзорная статья2016Цитирований: 2
ABI
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30
Статья2017Цитирований: 2
ABI
Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
Обзорная статья2017Цитирований: 2
ABI
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo‐Jack, Alice T. Shaw
Обзорная статья2017Цитирований: 2
ABI
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Flávia Castro, Ana Patrícia Cardoso, Raquel M. Gonçalves +2
Обзорная статья2018Цитирований: 2
ABI
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Jung-Mao Hsu, Weiya Xia, Yi‐Hsin Elsa Hsu +14
Статья2018Цитирований: 2
ABI
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
Jong‐Ho Cha, Wenhao Yang, Weiya Xia +25
Статья2018Цитирований: 2
ABI
Role of the immunosuppressive microenvironment in immunotherapy
Garth W. Tormoen, Marka R. Crittenden, Michael J. Gough
Обзорная статья2018Цитирований: 2
ABI
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon, Daniela Bruni
Обзорная статья2019Цитирований: 2
ABI
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Christopher M. Jackson, John Choi, Michael Lim
Обзорная статья2019Цитирований: 2
ABI
Extracellular Vesicle- and Extracellular Vesicle Mimetics-Based Drug Delivery Systems: New Perspectives, Challenges, and Clinical Developments
Prakash Gangadaran, Byeong‐Cheol Ahn
Обзорная статья2020Цитирований: 2
ABI
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
Lucia Lisi, Pedro Miguel Lacal, Maria Martire +2
Обзорная статья2021Цитирований: 2
ABI
VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment
Yueshui Zhao, Sipeng Guo, Jian Min Deng +13
Обзорная статья2022Цитирований: 2
ABI
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu, Yali Zhou, Mingming Zhang +25
Статья2022Цитирований: 2
ABI
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M. Devlin, Jonathan Landa +35
Статья2022Цитирований: 2
ABI
Без названия
ДругоеЦитирований: 1
ABI
Без названия
ДругоеЦитирований: 1
ABI
Без названия
ДругоеЦитирований: 1
ABI
Без названия
ДругоеЦитирований: 1
ABI
Без названия
ДругоеЦитирований: 1
ABI